Dabrafenib Plus Trametinib Shows Improved Survival in Phase II Trial for BRAF V600 Melanoma
June 6th 2016Treatment with dabrafenib (Tafinlar) plus trametinib (Mekinist) resulted in a complete response in 9 of 19 patients with stage IIIb/c BRAF V600 melanoma, according to results from a phase II trial presented at the 2016 ASCO Annual Meeting.
Read More
Joint Trial Analysis Confirms Benefit of Anthracyclines in High-Risk Breast Cancer
June 6th 2016A joint analysis of the "ABC" trials comparing anthracycline versus non-anthracycline treatment in patients with high-risk, HER2-negative breast cancer has failed to demonstrate non-inferiority of the non-anthracycline regimen.
Read More
Earlier Nab-Paclitaxel/Gemcitabine Explored in Pancreatic Cancer
March 15th 2016A bevy of clinical trials exploring the use of nab-paclitaxel (Abraxane) in various combinations and treatment settings aim to uncover future strategies for treating patients with pancreatic adenocarcinoma, which remains one of the deadliest forms of cancer.
Read More
Dr. Manish Shah on Treatment Options for Patients With Locally Advanced Stomach Cancer
February 2nd 2016Manish Shah, MD, Bartlett Family Associate Professor of Medicine, director, Gastrointestinal Oncology Program, Weill Cornell Medical College, discusses doing more than just surgery for patients with locally advanced stomach cancer.
Read More
Dr. Kenneth Wang on Forgoing Screening for Barrett's Esophagus
February 2nd 2016Kenneth Wang, MD, director of the Advanced Endoscopy Group and Esophageal Neoplasia Clinic, Mayo Clinic, discusses his opposition for Barrett's esophagus screening as a preventative measure for esophageal adenocarcinoma.
Watch
Dr. Keith Wilson on the Role of Helicobacter Pylori in Gastrointestinal Cancer
January 30th 2016<div style="color:#003668"><em>"When there is a mismatch between the human genetics and bacterial genetics, this may be one of the factors that leads to gastrointestinal cancer."<p align="right"><span style="color:#747474">- Keith Wilson, MD</span></em></div></p>
Watch
Second-Line Treatment for Metastatic Pancreatic Cancer Feasible and Beneficial
January 27th 2016Second-line treatment of metastatic pancreatic cancer proved to be feasible and beneficial, particularly for patients who received nab-paclitaxel in addition to gemcitabine, according to extension data from a phase III trial.
Read More
Analysis Shows Pancreatic Cancer Survival Rates Lower in Real World Than Clinical Trials
January 27th 2016Patients with pancreatic adenocarcinoma enrolled on clinical trials have "profoundly improved survival" compared with patients in the general population, suggesting that oncologists who use trial data to prognosticate may be missing the mark, according to researchers whose work was presented at the 2016 Gastrointestinal Cancers Symposium.
Read More
First-in-Class Cancer Stemness Inhibitor Shows Promising Results in Advanced Colorectal Cancer
January 27th 2016The latest results from an open-label, phase Ib study of the STAT3 inhibitor BBI-608 (napabucasin) with a standard chemotherapy (FOLFIRI with or without bevacizumab) in the treatment of advanced colorectal cancer, have been presented at the ASCO 2016 Gastrointestinal Symposium. Evidence of antitumor activity and a favorable safety profile were seen in phase I studies.
Read More
Avelumab Shows Clinical Activity in Advanced Gastric and GEJ Cancer
January 27th 2016Avelumab, an investigational anti-PD-L1 antibody, showed clinical activity as both a second-line and maintenance therapy in patients, with unresectable gastric or gastroesophageal junction (GEJ) cancer, according to data from a phase Ib presented at the 2016 Gastrointestinal Cancers Symposium.
Read More
Oral Stemness Inhibitor Shows Responses in Heavily Pretreated Metastatic Pancreatic Cancer
January 27th 2016An orally administered first-in-class cancer stemness inhibitor, BBI608, administered twice daily with weekly paclitaxel has promising activity in patients with refractory, heavily pretreated metastatic pancreatic cancer; particularly in patients who are taxane naive.
Read More
Nivolumab Exhibits Clinical Activity in Gastric Cancer
January 26th 2016Nivolumab (Opdivo) produced an overall response rate (ORR) of 14% with an acceptable safety profile in patients with gastric or gastroesophageal junction (GEJ) cancer, according to data from the phase I/II CheckMate-032 trial.
Read More
Dr. Cathy Eng on Bevacizumab Plus FOLFOXIRI for Patients With mCRC.
January 22nd 2016Cathy Eng, MD, FACP, medical oncologist, The University of Texas MD Anderson Cancer Center, discusses the combination of bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as a treatment for patients with metastatic colorectal cancer (mCRC).
Watch
Updated Data Shows Sustained OS Advantage for Liposomal Irinotecan in Pancreatic Cancer
January 21st 2016Combining liposomal irinotecan (nal-IRI; MM-398; Onivyde) with 5-fluorouracil (5-FU) plus leucovorin dropped the risk of death in patients with metastatic pancreatic cancer by 25% following progression on a gemcitabine-based regimen, according to updated data from the phase III NAPOLI-1 trial.
Read More
Neoadjuvant Radiation Regimen Efficacious, Less Toxic in Patients With Rectal Cancer
January 20th 2016Preoperative treatment with short-course radiation therapy plus 3 cycles of chemotherapy boosted overall survival (OS) and generated fewer adverse events (AEs) compared to standard chemoradiation for patients with locally advanced rectal cancer.
Read More
Everolimus Becomes the New Standard of Care for Patients With GI NETs
January 20th 2016Patients with either gastrointestinal (GI) neuroendocrine tumors (NETs) or NETs of unknown primary origin experienced a 40% or more decrease in their risk of disease progression when treated with everolimus (Afinitor), according to a subanalysis of the phase III RADIANT-4 trial.
Read More
Lu-Dotatate Continues to Offer Major Benefits to Patients With Midgut NETs
January 20th 2016Patients with advanced midgut neuroendocrine tumors (NETs) will continue to see major therapeutic benefits from the peptide receptor radionuclide therapy Lu-Dotatate (Lutathera), including an improvement in overall survival and the reduction of progression or death risk by 79%.
Read More
Dr. James L. Gulley on Atezolizumab, Pembrolizumab, and Avelumab's Potential Uses in Bladder Cancer
January 11th 2016Gulley says there are currently a variety of phase III studies looking at new treatments for use in bladder cancer, despite some widely-used agents, such as nivolumab and pembrolizumab, already being approved for other cancer types like melanoma and lung cancer, though not bladder cancer.
Watch